Search Results
MC# 21-22
A Phase I/II Randomized, Double-Blind, Placebo-Controlled Trial (1-Better) Examining Xb2001 (Anti-Il-1⍺ True Human Antibody) In Combination With Onivyde + 5-Fluorouracil + Leucovorin In Advanced Pancreatic Cancer
MC# 22-17
Phase I/Ib Multicenter Open-Label Study of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS
MC# 21-23
A Phase I Dose-Escalation and Dose Expansion Study of TJ033721 in Subjects with Advanced or Metastatic Solid Tumors
MC# 22-19
Phase I/II Safety and Efficacy Study of NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
MC# 20-13
An Open-label Phase Ib/IIa Study of NT-I7 (efineptakin alfa) in Combination with Pembrolizumab in Subjects with Relapsed/Refractory Advanced Solid Tumors
MC# 22-26
A Phase I/II Multicenter, Open-label, Dose-escalation, Safety, Pharmacodynamic, and Pharmacokinetic Study of Q901 Administered via Intravenous Infusion in Adult Patients with Selected Advanced Solid Tumors with a Cohort Expansion at the Recommended Phase 2 Dose
MC# 20-41
A Phase Ia/Ib Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PY159 as a Single Agent and In Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
MC# 22-10
A Phase I First-in-human Study of BMS-986406 as Monotherapy and Combination Therapies in Participants with Advanced Malignant Tumors
MC# 22-42
A First-in-human, Multicenter, Open-label, Dose Escalation and Dose Expansion Phase I Study in Patients with Advanced Solid Tumors to Evaluate the Safety of Intravenously Administered ALG.APV-527
